DEERFIELD, Ill.--(BUSINESS WIRE)--July 19, 2006--Dade Behring Inc. (NASDAQ:DADE - News), the world’s largest company solely dedicated to clinical diagnostics, today announced that it has launched the Tacrolimus test for use on its Dimension® family of chemistry analyzers and V-Twin® and Viva-E(TM) drug testing analyzers. This test further expands Dade Behring’s offering of immunosuppressant drug tests used by physicians to monitor organ rejection in patients who have recently received an organ transplant.
